NHS England to fund Duodopa

News

Author: Parkinson's Life editorsPublished: 28 August 2015

Prep: Cook: Serves:

The NHS in England has announced they will fund Duodopa – a life-changing drug for people with advanced Parkinson’s – after campaigners managed to garner the support of nearly a hundred MPs who signed a petition.

This means that should a specialist Parkinson’s clinician prescribe Duodopa, a patient will be able to receive it without delay. Duodopa can help to control the symptoms of advanced Parkinson’s when all other treatments have stopped working.

The petition signed by 98 MPs put pressure on NHS England to act urgently to address the situation.

Laura Cockram, policy and campaigns manager at Parkinson’s UK said: “I am elated that the NHS has finally arrived at this decision. We know this treatment has had transformative effects on many that have been treated with it and how vital it is that those who need Duodopa receive it without delay. This is an important day for Parkinson’s care.”

Last Month

Next Month

Go Back

Share this story

Comments

Global update

‘Chopsticks are not easy for a person with Parkinson’s’

In the third in our series on this year’s World Parkinson Congress (WPC),

Sign up to Nordic walking and beach fitness at Parkinson’s bootcamp

Spaces now available for summer exercise camp in Portugal

Journalist Liz Jackson’s emotional film about her Parkinson’s is “TV at its finest”

An outpouring of sympathy for award-winning journalist

New biotech to drive forward GDNF treatment for Parkinson’s disease

UK charity Parkinson’s UK is creating a new company, Vivifi Biotech, to develop a treatment with potential to stop or reverse Parkinson’s disease. The experimental therapy surgically distributes GDNF, a protein that is naturally produced by the brain to protect cells, directly into the brain. The charity previously funded a clinical trial to investigate whether boosting GDNF levels could regenerate dying brain cells in people with Parkinson’s. Over the next two years, it will invest up to £800,000 to prepare for a second trial. Arthur Roach, head of research at Parkinson’s UK, said: “While our initial trial didn’t meet its critical endpoint, it did reveal robust evidence indicating that GDNF can possibly reverse Parkinson’s. This is why Parkinson’s UK is committed to continuing research into this potential treatment.” Vivifi Biotech, Roach added, will “bring the right people together to plan a new trial that meets the needs of patients, regulatory…

New wearable medical device for Parkinson’s disease to launch this year

The Imperial College London Innovation Fund, UK, has invested £205,000 to support UK-based tech company Charco Neurotech in its development of a non-invasive medical device for people with Parkinson’s disease. CUE1, a circular device that attaches to the sternum with medical adhesives, uses specialised vibration to help alleviate physical symptoms of Parkinson’s disease. Initial user testing among people with the condition found that the device improved movement by an average of 16%, with testers reporting benefits for walking and fine motor tasks. Lucy Jung, CEO and co-founder of Charco Neurotech, said: “We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology. We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials.” Charco Neurotech will use the Imperial College investment to initiate a clinical trial and fund the device’s manufacture for…

New study brings scientists a “vital step” closer to understanding Parkinson’s disease

A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

NHS England to fund Duodopa

News

Author: Parkinson's Life editorsPublished: 28 August 2015

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Global update

‘Chopsticks are not easy for a person with Parkinson’s’

Health & Fitness

Sign up to Nordic walking and beach fitness at Parkinson’s bootcamp

Perspectives

Journalist Liz Jackson’s emotional film about her Parkinson’s is “TV at its finest”

New biotech to drive forward GDNF treatment for Parkinson’s disease

New wearable medical device for Parkinson’s disease to launch this year

New study brings scientists a “vital step” closer to understanding Parkinson’s disease

{title}

Subscribe

NHS England to fund Duodopa

News

Author: Parkinson's Life editorsPublished: 28 August 2015

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Global update

‘Chopsticks are not easy for a person with Parkinson’s’

Health & Fitness

Sign up to Nordic walking and beach fitness at Parkinson’s bootcamp

Perspectives

Journalist Liz Jackson’s emotional film about her Parkinson’s is “TV at its finest”

New biotech to drive forward GDNF treatment for Parkinson’s disease

New wearable medical device for Parkinson’s disease to launch this year

New study brings scientists a “vital step” closer to understanding Parkinson’s disease

{title}

Subscribe

Sign in